Journal: Frontiers in Immunology

Article Title: Insight into immune profile associated with vitiligo onset and anti-tumoral response in melanoma patients receiving anti-PD-1 immunotherapy

doi: 10.3389/fimmu.2023.1197630

Figure Lengend Snippet: IL-17-expressing cells are differently modulated in the skin lesion and in the circulation of melanoma patients developing vitiligo during anti-PD-1 therapy. (A) Representative images of the immunohistochemistry (panels a to d) and immunofluorescence (panels e, f) analysis performed using antibodies directed against CD56 (panels a–c), IL-17 (panels d–f) and TCR alpha V 7.2 (panels g–i) on normal skin biopsies and on biopsies from patients affected by vitiligo without melanoma (vitiligo) and who developed vitiligo during immunotherapy (vitiligo DI). Magnification 200x. (B) Quantitative analyses of immunohistochemical staining. The mean value + standard error of the mean (SEM) of the cell count obtained for five different fields is shown, ***p<0.05 as assessed by Kruskal-Wallis test.

Article Snippet: For immunofluorescence, 4-µm sections were dewaxed, rehydrated, and after quenching endogenous peroxidase with 3% bovine serum albumin in 1x phosphate buffer, achieving antigen retrieval and blocking non-specific binding sites, sections were incubated with the monoclonal antibody anti-TCR V alpha 7.2 FITC conjugated (cod.130-123-929, Miltenyi Biotech; 1:50) and incubated for 1 hour at 37°C in a humid chamber.

Techniques: Expressing, Immunohistochemistry, Immunofluorescence, Staining, Cell Counting

Journal: Frontiers in Immunology

Article Title: Insight into immune profile associated with vitiligo onset and anti-tumoral response in melanoma patients receiving anti-PD-1 immunotherapy

doi: 10.3389/fimmu.2023.1197630

Figure Lengend Snippet: Expression of the immune cell subsets in the primary melanoma and metastases of patients developing or not vitiligo during anti-PD-1 therapy. (A) Representative images of immunohistochemistry (panels a to i) and immunofluorescence (l–n) obtained using anti-CD25 (a–c), anti-CD56 (d–f), anti-IL-17A (g–i), and anti-TCR alpha V 7.2 (j–l) in primary melanoma and metastasis from patients who developed (vitiligo) or not vitiligo (not vitiligo) during therapy. A–I 100x magnification, panel L-N 200X magnification. Magnification 200x. (B) Quantitative analyses of immunohistochemical staining. The mean value + standard error of the mean (SEM) of the cell count obtained for five different fields is shown, *p<0.05 as assessed by Kruskal-Wallis test.

Article Snippet: For immunofluorescence, 4-µm sections were dewaxed, rehydrated, and after quenching endogenous peroxidase with 3% bovine serum albumin in 1x phosphate buffer, achieving antigen retrieval and blocking non-specific binding sites, sections were incubated with the monoclonal antibody anti-TCR V alpha 7.2 FITC conjugated (cod.130-123-929, Miltenyi Biotech; 1:50) and incubated for 1 hour at 37°C in a humid chamber.

Techniques: Expressing, Immunohistochemistry, Immunofluorescence, Staining, Cell Counting